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Introduction: We report the seventh case of Chryseobacterium indologenes occurring in the United States of
America. C. indologenes is seldom isolated from clinical specimens but has caused hospital-acquired infections in
Taiwan and rarely elsewhere.
Case presentation: A 32-year-old Caucasian woman with metastatic breast cancer presented to a hospital
emergency department with bilateral radiation-induced pleural effusions and respiratory failure. The patient was
hospitalized and ventilated for 26 days; tracheal aspirates collected on ventilation days 24 and 26 grew C.
indologenes. The patient subsequently died as a result of worsening ventilator-associated pneumonia and stage IV
breast cancer.
Conclusions: C. indologenes infection should be considered for hospitalized patients with a history of malignancy,
especially those with indwelling devices and antibiotic use for >14 days.
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We report the seventh case of Chryseobacterium
indologenes in the United States of America (USA),
occurring in a Caucasian woman aged 32 years with
metastatic breast cancer. C. indologenes is a rare human
pathogen reported to have caused hospital-acquired in-
fections in Taiwan and rarely elsewhere: six cases have
been reported in Europe, two in Australia, and four in
the USA [1-4]. In addition, ophthalmic C. indologenes
infections have been reported including one case report
in the USA, one in Taiwan and one in Spain [5-7]. C.
indologenes was first isolated from a clinical specimen in
1993 from the tracheal aspirate of a patient with
ventilator-associated pneumonia. The Gram-negative
bacillus is ubiquitous in soil and water, but it has not
been found in human microflora and is rarely isolated
from clinical specimens. C. indologenes can survive* Correspondence: syasmin@cdc.gov
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reproduction in any medium, provided the orchlorination, is found in municipal water supplies, and
can colonize sink basins and taps [8,9]. C. indologenes
has also been found in medical devices that use water,
for example humidifiers and ventilators [9]. The
Chryseobacterium species form circular, convex, bright-
yellow colonies on blood, Tryptic soy, or nutrient agar;
however, it grows poorly on MacConkey medium [10].
Chryseobacterium bacteria are known to be resistant to
extended spectrum penicillin, first and second gene-
ration cephalosporins and aztreonam; susceptibility to
quinolones, aminoglycosides and cephalosporins varies.
Combination antimicrobial therapy with trimethoprim-
sulfamethoxazole and rifampin has been successful in
treating C. indologenes infection [11,12]. Studies in
Taiwan have indicated hospitalization, cancer and
prolonged antibiotic treatment (>14 days) as risk factors
for infection [9,13].
Case presentation
A 32-year-old Caucasian woman was diagnosed with
breast cancer and treated with radiation and mastec-
tomy with immediate flap reconstruction and implant
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was identified during an out-patient thoracentesis for
radiation-induced pleural effusions. The patient was
admitted to a hospital where she was treated with
pericardial window drainage of the effusion. She was
discharged home on intravenous antibiotics (vanco-
mycin, fluconazole) and analgesia. At home, she conti-
nued to use unspecified naturopathic therapies that she
had been taking since the mastectomy and of which
further details are unknown. Ten days post-discharge,
the patient suffered a cardiac arrest at home and was
admitted to hospital where mechanical ventilation was
initiated and bilateral chest drains inserted. Eleven days
later, a tracheostomy was performed. Two tracheal
aspirate samples taken on ventilation days 24 and 26
grew C. indologenes. The isolate was susceptible to
co-trimoxazole, ciprofloxacin, and levofloxacin. The
patient received a diagnosis of ventilator-associated
pneumonia and was treated with levofloxacin. Her white
blood cell count, which had remained within normal
limits until ventilation day 24, peaked at 19 × 109/L on
ventilation day 26. The patient died from cardio-
respiratory failure and complications of stage IV meta-
static breast cancer 40 days after admission.
Only five cases of non-ophthalmic and one case of
ophthalmic C. indologenes have previously been reported
in the USA. In 2001, a 77-year-old man with a history of
curettage for squamous cell carcinoma of the leg
developed cellulitis of the leg. Wound cultures grew
C. indologenes that was susceptible to trimethoprim-
sulfamethoxazole and levofloxacin. The patient reco-
vered following treatment with oral levofloxacin [3].
In 2004, a case occurred in a man aged 54 years with a
metastatic squamous cell carcinoma of the nasal tube.
After radiation and chemotherapy, he was fed through a
gastrostomy. On hospital day 46, he experienced a fever
but had a normal white blood cell count. Blood cultures
obtained through a peripheral venous catheter were
positive for C. indologenes, and the patient was success-
fully treated with piperacillin-tazobactam and removal of
the catheter [4].
A case reported in 2006 was in a Caucasian woman aged
57 years with metastatic breast cancer. An indwelling
catheter through which she received chemotherapy had
been colonized by C. indologenes, resulting in pea-sized
nodules and yellow discoloration of the skin surrounding
the catheter. This patient recovered after treatment with
ciprofloxacin [1].
In 2007, the first case of C. indologenes central ner-
vous system infection was reported in a 13-year-old boy
with congenital hydrocephalus and a lumboperitoneal
shunt. The patient was successfully treated with com-
bination treatment with trimethoprim-sulfamethoxazole
and rifampin [2].The first case of subcutaneous port-related C. indologenes
infection in a liver transplant recipient was reported in
2013 [14]. The patient, a 26-year-old woman had received a
liver transplant 6 years prior to the infection and was on an
established immunosuppressive regime. Blood cultures
drawn from the port grew C. indologenes; susceptibility tes-
ting revealed resistance to piperacillin-tazobactam, other
broad-spectrum β-lactams and aminoglycosides. The pa-
tient was treated with intravenous levofloxacin and oral
trimethoprim-sulfamethoxazole. However, device removal
was also necessary.
Conclusions
Multiple factors placed the patient at risk for C. indologenes
infection, including her breast cancer, recent surgery, mul-
tiple indwelling devices (for example, a peripherally inserted
central catheter, bilateral chest tubes, tracheostomy, and a
urinary catheter), mechanical ventilation for 39 days, and
intravenous antibiotic treatment for 90 days. C. indologenes
infection can be considered a rare opportunistic pathogen
among hospitalized patients with a history of malignancy,
especially those with indwelling devices and antibiotic use
for >14 days.
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